山东烟台地区HCV感染的基因分型研究

目的 了解山东烟台地区丙型肝炎病毒的基因分型,结合受试者的肝功能指标观察基因型别与肝损情况是否相关.方法 采用特异性PCR引物对HCV RNA5'UTR区和(或)NS5B区进行扩增,PCR产物进行序列分析,通过与GenBank中参考序列的比对,联合遗传进化树对标本予以分型.结果 9例无偿献血员中检出1b和3a两种基因亚型,分别为8例和1例.33例丙肝患者中,检出1b、2a和6a三种基因亚型,分别为22(66.7％)、10(30.3％)和1(3.03％)例.1b亚型是烟台地区HCV携带者的优势流行基因亚型,在不同人群中分布差异无统计学意义(x2=0.796,P=0.373)；不同基因分型的受试者其肝损指标的差异有统计学意义(P＜0.05),2a型携带者的ALT、AST均值明显高于1b型.结论 山东烟台地区HCV基因型呈现多样性,以1b为主,并首次检出3a和6a亚型.HCV基因型与肝损指标具有相关性,2a型HCV感染可能在肝细胞的病变过程中起着重要作用.

Study on hepatitis C virus genotypes in Yantai district, Shandong province

Objective To understand the hepatitis C virus （HCV） genotype distribution in Yantai district of Shandong province,and to explore whether the HCV genotypes was relevant to the injure of liver through the index of liver function. Methods Using specific PCR primers to amplify the HCV RNA 5 ＇ UTR/NS5B,then PCR products were sequenced by genetic analyzer. The genotypes were identified by alignment to the GenBank reference sequences and construction the phylogenetic tree of 5 ＇ UTR. Results Among 9 unpaid blood donors we detected two kinds of genotypes of lb and 3a, respectively, 8 cases （88.9%） and 1 case （ 11.1% ）. Among 33 cases of hepatitis C patients wedetected the lb,2a and 6a the three kinds of genotypes, respectively, 22 （ 66. 7% ） , 10 （ 30.3% ） and 1 （ 3.03% ） cases. Subtype 1 b is the advantage of popular genotype in HCV carriers from Yantai district, and the distribution of lb was no significant difference in the different population （X2 = 0. 796 ,P = 0. 373 ） ; The difference of indicator of liver damage in the different genotypes of subjects were significant （P 〈 0. 05） , the mean of ALT, AST of 2a- subtype carriers was significantly higher than the lb-subtype population. Conclusions The genetic diversity of HCV in Shandong Yantai district was presented. The main genotypes were lb-subtype, and 3a and 6a- subtype was detected firstly. The genotype of HCV were relevant to the liver damage indicators,2a-subtype hepatitis C virus infection in the liver cells may play an important role in the disease process.